Betulinic Acid Decorated with Polar Groups and Blue Emitting BODIPY Dye: Synthesis, Cytotoxicity, Cell-Cycle Analysis and Anti-HIV Profiling
Authors:
- David KodrDKDavid Kodr
- Jarmila StankováJSJarmila Stanková
- Michaela RumlováMRMichaela Rumlová
- Petr DžubákPDPetr Džubák
- Jiří ŘehulkaJŘJiří Řehulka
- Tomáš ZimmermannTZTomáš Zimmermann
- Ivana KřížováIKIvana Křížová
- Soňa GurskáSGSoňa Gurská
- Marián HajdúchMHMarián Hajdúch
- Pavel B. DrašarPavel B. Drašar
- Michal JurášekMichal Jurášek
Open Access
- 28 August 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (9) , 1104
Abstract
Betulinic acid (BA) is a potent triterpene, which has shown promising potential in cancer and HIV-1 treatment. Here, we report a synthesis and biological evaluation of 17 new compounds, including BODIPY labelled analogues derived from BA. The analogues terminated by amino moiety showed increased cytotoxicity (e.g., BA had on CCRF-CEM IC50 > 50 μM, amine 3 IC50 0.21 and amine 14 IC50 0.29). The cell-cycle arrest was evaluated and did not show general features for all the tested compounds. A fluorescence microscopy study of six derivatives revealed that only 4 and 6 were detected in living cells. These compounds were colocalized with the endoplasmic reticulum and mitochondria, indicating possible targets in these organelles. The study of anti-HIV-1 activity showed that 8, 10, 16, 17 and 18 have had IC50i > 10 μM. Only completely processed p24 CA was identified in the viruses formed in the presence of compounds 4 and 12. In the cases of 2, 8, 9, 10, 16, 17 and 18, we identified not fully processed p24 CA and p25 CA-SP1 protein. This observation suggests a similar mechanism of inhibition as described for bevirimat.Keywords
Funding Information
- Grantová Agentura České Republiky (GA20-19906S)
- Ministerstvo Školství, Mládeže a Tělovýchovy (LM2018130, LM2018133)
This publication has 59 references indexed in Scilit:
- HIV-1 Assembly, Budding, and MaturationCold Spring Harbor Perspectives in Medicine, 2012
- The G-Patch Domain of Mason-Pfizer Monkey Virus Is a Part of Reverse TranscriptaseJournal of Virology, 2012
- A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor BevirimatAntimicrobial Agents and Chemotherapy, 2011
- Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to BevirimatAntimicrobial Agents and Chemotherapy, 2010
- Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimatRetrovirology, 2010
- Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissueRetrovirology, 2010
- Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1Antimicrobial Agents and Chemotherapy, 2009
- Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2007
- Multiple-Dose Pharmacokinetics and??Safety of Bevirimat, a??Novel??Inhibitor??of??HIV Maturation,??in??Healthy??VolunteersClinical Pharmacokinetics, 2007